Literature DB >> 18317640

Revision of the Sokolow-Lyon-Rappaport and cornell voltage criteria for left ventricular hypertrophy.

Sérgio Lamêgo Rodrigues1, Lílian D'Angelo, Alexandre Costa Pereira, José Eduardo Krieger, José Geraldo Mill.   

Abstract

BACKGROUND: Electrocardiographically-detected left ventricular hypertrophy (LVH) is a strong predictor of cardiovascular morbidity and mortality.
OBJECTIVE: To assess the performance of the Sokolow-Lyon-Rappaport (SLR) and Cornell voltage criteria in a population sample regarding the diagnosis of LVH on echocardiogram (ECHO).
METHODS: A total of 641 out of the 682 participants of the second phase of the MONICA-Vitória project were assessed using electrocardiogram and echocardiogram. A subgroup of healthy individuals (n=269) was used to generate reference values of LV mass (LVM). Sensitivities and specificities of the electrocardiographic criteria were determined by the ROC (receptor-operator characteristics) curve in relation to the diagnosis of LVH, as defined by the internal echocardiographic criterion (LVM > 48 and 46 g/m2.7 for males and females, respectively).
RESULTS: The prevalence of LVH as detected by ECHO was 23.7% in the total sample, in which 49% of the individuals were hypertensive. The Cornell criterion showed a better association with the LVM as estimated by ECHO (r= 0.37, p < 0.01) than the SLR criterion (r= 0.19) as well as a better performance in the analysis of the area under the ROC curve. The new cut-off points for the internally-defined Cornell voltage criterion (2.3 mV for males and 1.9 mV for females) showed an acceptable combination of sensitivity (22.5 and 28% for males and females, respectively), with a high specificity (95%).
CONCLUSION: The classic SLR and Cornell voltage criteria showed a low performance in relation to LVH as detected by the ECHO. However, this accuracy may be improved by using the Cornell voltage criteria defined in the present study.

Entities:  

Mesh:

Year:  2008        PMID: 18317640     DOI: 10.1590/s0066-782x2008000100008

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  6 in total

1.  Detection of left ventricular hypertrophy by the R-wave voltage in lead aVL: population-based study.

Authors:  Sérgio Lamêgo Rodrigues; Lílian Cláudia Souza Angelo; Marcelo Perim Baldo; Eduardo Miranda Dantas; Alexandre Maulaz Barcelos; Alexandre C Pereira; José Eduardo Krieger; José Geraldo Mill
Journal:  Clin Res Cardiol       Date:  2013-05-10       Impact factor: 5.460

2.  The occurrence of left ventricular hypertrophy in normotensive individuals in a community setting in North-East Trinidad.

Authors:  Romel Bacchus; Kristianna Singh; Ijaz Ogeer; Kameel Mungrue
Journal:  Vasc Health Risk Manag       Date:  2011-07-06

3.  Consistency of left ventricular hypertrophy diagnosed by electrocardiography and echocardiography: the Northern Shanghai Study.

Authors:  Wei Zhang; Yiwu Zhou; Bin Bai; Shikai Yu; Jing Xiong; Chen Chi; Jiadela Teliewubai; Jue Li; Jacques Blacher; Yi Zhang; Yawei Xu
Journal:  Clin Interv Aging       Date:  2019-03-11       Impact factor: 4.458

4.  Peguero-Lo Presti criteria for the diagnosis of left ventricular hypertrophy: A systematic review and meta-analysis.

Authors:  Zongying Yu; Jie Song; Li Cheng; Shasha Li; Qun Lu; Yafeng Zhang; Xiaoci Lin; Dadong Liu
Journal:  PLoS One       Date:  2021-01-29       Impact factor: 3.240

5.  A comparison of cornell and sokolow-lyon electrocardiographic criteria for left ventricular hypertrophy in korean patients.

Authors:  Jin Kyu Park; Jeong Hun Shin; Seok Hwan Kim; Young-Hyo Lim; Kyung-Soo Kim; Soon Gil Kim; Jeong Hyun Kim; Heon Gil Lim; Jinho Shin
Journal:  Korean Circ J       Date:  2012-09-27       Impact factor: 3.243

6.  Determinants and improvement of electrocardiographic diagnosis of left ventricular hypertrophy in a black African population.

Authors:  Ahmadou M Jingi; Jean Jacques N Noubiap; Philippe Kamdem; Samuel Kingue
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.